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The Genes, Environment, and Development
Initiative (U01)
This Request for Applications (RFA) from the
National Institute on Drug Abuse (NIDA) and the
National Cancer Institute (NCI) launches the Genes,
Environment, and Development Initiative (GEDI).
The GEDI will support research using existing
research samples to investigate main effects, correla-
tions, and interactions among genetic, environmen-
tal, and developmental factors in the etiology of
substance abuse and related phenotypes in humans.
The term "substance abuse" as used in this RFA
refers broadly to several different but related concepts
including substance use (quantity, frequency, pat-
terns, trajectories) and substance abuse and depen-
dence as defined by diagnostic criteria. While it is
recognized that these concepts may not be inter-
changeable, the term “substance abuse” is used for
the purposes of ﬂuency. The term “substance” refers
primarily to nicotine, alcohol, cannabis, cocaine,
stimulants, and opiates, but also includes the entire
range of licit and illicit substances of potential addic-
tion. The term “related phenotypes” refers to con-
structs that have been shown empirically to convey
risk for substance abuse, such as behavioral disinhibi-
tion. “Developmental research” refers to the study of
progressive change that occurs as humans move
through the lifecourse.
The National Institute on Mental Health
(NIMH) has an interest in applications where the
research contributes to knowledge about the inter-
play of genetic, environmental, and developmental
factors in the etiology of adverse outcomes; however,
no funds will be committed at this time.
Prior lines of research have established that
genetic, environmental, and developmental factors all
contribute to vulnerability to substance abuse and
related phenotypes. Both animal and human studies
have demonstrated genetic influences on substance
abuse, with heritability estimates ranging from 40 to
60%, and promising candidate loci and genes for sub-
stance abuse have been identiﬁed. Genetic inﬂuences
have also been shown for many related phenotypes,
and some (e.g., externalizing disorders) share genetic
factors with substance abuse. As with other complex
disorders, it is likely that multiple genes of small
effects contribute to vulnerability to substance abuse
and related phenotypes, and that environmental con-
ditions moderate genetic inﬂuence. A wide variety of
environmental variables have been correlated with
substance abuse and related phenotypes, including
in utero exposures, parenting, trauma and stress, peer
inﬂuences and/or neighborhood and societal factors.
Many of these correlations have been very strong and
frequently replicated, forming the basis for numerous
preventive intervention studies with youth at high risk
due to individual and familial factors in combination
with the social context over the course of develop-
ment. The role of developmental factors is highlighted
not only by the fact that the human brain is an organ
that continues to develop until the mid-twenties, but
also by the changes in substance abuse patterns associ-
ated with signiﬁcant developmental shifts, including
childhood transitions, pubertal transitions (often coin-
ciding with substance use initiation), transitions to
greater independence after high school (associated
with increased substance use and shifts from use to
dependence), and adult role transitions such as mar-
riage, parenting, and full time employment (associated
with decreased substance abuse). Although less well
understood, developmental timing of substance abuse
has been assumed to be important as well, with differ-
ent outcomes (e.g., addiction) expected depending on
when certain events (e.g., onset of substance use)
occur over the life course. Expression patterns of genes
associated with substance abuse change over the
course of development, either through epigenetic
modiﬁcations that are developmental and tissue spe-
ciﬁc, or through genetic variation that may affect gene
expression during certain stages of neurodevelopment.
For instance, animal studies have shown that exposure
to nicotine during adolescence, compared to adult-
hood, predicts greater drug-seeking behavior and neu-
rologic change in critical areas of the brain. Similarly,
human research has shown that prenatal exposure to
nicotine increases the risk of nicotine dependence dur-
ing adulthood. 
While these lines of research have made impor-
tant contributions to our understanding of substance
abuse, they each have limitations in delineating the
etiology of substance abuse and related phenotypes,
and they can benefit from integration and interac-
tion with the others. The inferential power of envi-
ronmental and developmental studies can be
signiﬁcantly enhanced by the inclusion of analyses of
gene–environment correlations, that is, genetic inﬂu-
ences on environmental exposures. For example, by
accounting for family history or genetic susceptibil-
ity to substance abuse, studies of prenatal-exposure
effects on later behavior can better determine the
role of passive gene–environment correlation, which
in turn can help distinguish between exposure effects
and family history as the source of behavioral out-
comes. Similarly, studies of peer influences or par-
enting behaviors in adolescence will be strengthened
by taking into account passive, active, and evocative
gene–environment correlations, which can help to
clarify the role of the adolescent’s choices and behav-
iors in eliciting these environmental factors. In addi-
tion, molecular genetics studies seeking to identify
speciﬁc susceptibility genes can be greatly enhanced
in their power and accuracy by attending to interac-
tions with environmental and developmental factors
that may affect the expression of these genes.
Over many years, NIDA, other NIH institutes,
and other organizations have funded numerous high-
quality longitudinal and developmental studies that
contain a wealth of data from individuals who are at
risk for, or are in the course of development, progres-
sion, and desistance of, substance abuse and related
phenotypes. A valuable variety of variables associated
with these outcomes has been measured on diverse
samples across multiple domains and time points,
characterizing psychopathology, temperament, famil-
ial relations and practices, peer relations and charac-
teristics, school factors, and broader environmental
influences, as well as biological variables including
in utero and toxic exposures, endophenotypes, and
neurocognitive structure and function. In addition,
the many randomized intervention trials that have
been conducted over the years provide opportunities
for strong inferences about the role of social environ-
ment in causality by focusing on presumed etiologic
social factors and examining covariance of the social
environment and adjustment over time. The GEDI
seeks to build on this substantial public investment
by soliciting applications that integrate environmen-
tal and developmental variables with genotypic infor-
mation to permit comprehensive model building and
hypothesis testing for determining genetic, environ-
mental, and developmental contributions to sub-
stance abuse and related phenotypes. 
Applications qualifying for submission under this
FOA must rely exclusively on existing studies of
human subjects; new data collection is permitted only
for the purpose of obtaining blood from subjects so
that DNA and cryopreserved lymphocytes can be gen-
erated as a renewable resource and stored. Studies with
DNA already collected are required to demonstrate
that their DNA is a publicly available sharable
resource, with a clear process for access to the samples
by other qualiﬁed investigators. If the DNA samples
are stored at a site other than the NIDA repository,
plans for electronically depositing clinical data, pheno-
typic data, and genetic data into the NIDA Repository
for access and sharing need to be provided. If the col-
lection of new data is required to evaluate the disorder
(e.g., for studies where individuals are just entering the
period of risk for substance abuse), plans for collecting
these data through another funding mechanism should
be included. Data sets drawn from studies that involve
an intervention trial are appropriate for this RFA; these
proposals should address the approach to handling
intervention effects when exploring etiologic questions.
If intervention data sets are proposed for use to infer
causal inﬂuence (i.e., to explore whether intervening
on mediating variables changed outcomes in expected
ways, thus demonstrating the strength of the mediator
in “causing” the outcome of interest), then investiga-
tors must demonstrate successful randomization proce-
dures and sufficient power to detect and explicate
observed short- and long-term environmental inter-
vention effects in the sample. Proposals requesting sup-
port to collect new data other than DNA under this
RFA research mechanism or to conduct research using
animal models will be considered nonresponsive and
returned to the applicant.
Established studies/samples eligible for analyses
within GEDI applications must include the follow-
ing characteristics: 1) subjects who are in or through
the period of risk for substance abuse and related
phenotypes; 2) subjects who have provided the
appropriate consent for or can be recontacted for
additional consent for GEDI research (e.g., to per-
mit data sharing, blood collection, genetic analyses,
etc.); 3) DSMIIIR or DSMIV diagnoses as well as
other categorical and/or quantitative measures of
substance abuse and related phenotypes with
demonstrated heritability; 4) environmental data rel-
evant to substance abuse and related phenotypes; 5)
data waves spanning at least two developmental peri-
ods, such as in utero, infancy, early childhood, late
childhood, early adolescence, late adolescence,
emerging adulthood, and/or adulthood.
Applications should present a rationale that care-
fully balances important substantive, methodologic,
and budgetary issues. In particular, applications should
fully address each of the following points, where
applicable: 1) Sample selection (e.g., particularly infor-
mative subsamples and subgroups, understudied valu-
able populations); 2) Research design (e.g., genetically
informative, birth cohort, multigenerational, selection
by prenatal exposure, randomized intervention); 3)
Statistical power to detect the proposed main effects,
correlations, and interactions. In cases where individ-
ual data sets lack sufficient power to address study
aims, data from multiple sites may be pooled; 4)
Where pooling is planned, the application must
include procedures for combining data. In all cases
where multiple data sets are used, pilot data must be
provided within the application to demonstrate rea-
sonable compatibility of data across studies and evi-
dence of feasibility of multisample analyses; 5) In cases
where multiple data sets are used, evidence of
collaboration among sites must be shown; 6)
Generalizability of results [i.e., population(s) to which
findings can be applied]; 7) Phenotype(s) selection
(e.g., speciﬁc heritable phenotypes, related phenotypes,
endophenotypes); 8) Number and timing of assess-
ments (e.g., multiple waves ranging from pre- to post-
substance exposure, from substance use initiation to
disorder onset, or from disorder onset to remission);9) Selection and quality of assessments (e.g., diagnostic
and/or symptom-based scales, measurement of salient
individual and environmental factors); 10) comorbid-
ity (e.g., psychiatric, polysubstance, physical illness);
11) Timeline to collect and submit clean data (i.e.,
genetic, environmental, developmental data) to the
NIDA Repository; 12) Consent by subjects to allow
qualified investigators to use and analyze data and
DNA; 13) In view of the technical complexity of the
science called for in this announcement, the GEDI
requires transdisciplinary alliances among researchers
with appropriate breadth and depth of expertise.
Applications should have a substantial commitment of
personnel for statistical genetics and bioinformatics,
with detailed plans for data collection, storage, com-
munication, integration, analyses, and dissemination;
14) Proposals are required to include detailed plans
and timelines for replicating initial GEDI findings
within the 5-year award period. Plan(s) for replicating
should be fully explained and justiﬁed given that there
are many approaches for duplicating research ﬁndings
(e.g., reproducing results between randomly selected
subsamples samples from a single data set, replicating
findings across multiple data sets with comparable
measures, pooling data from multiple data sets and
replicating ﬁndings from randomly selected subsam-
ples); 15) Genotyping and analytic methodologies:
Applicants should note that the genotyping platform
ultimately chosen will be dependent upon an agree-
ment within the GEDI Steering Committee (described
in Section 6.2.A.3) to ensure consistent and standard
genotypes and allele names. Although the genotyping
approaches (candidate genes or whole genome scans,
for example) outlined for each funded grant may dif-
fer, the GEDI Steering Committee will be expected to
provide input on this effort among the cooperative
agreements so that a consensus strategy is achieved.
Nevertheless, a description and rationale of the plat-
form(s) proposed for genotyping should be included.
Applications should address the following: a) an
explicit rationale for the genotyping approach chosen
(candidate gene, linkage analysis, whole genome asso-
ciation); b) a plan to implement the genotyping and
milestones for achieving the genotyping in the time
frame of the funded period. This proposal should thor-
oughly discuss and justify the plans for genotyping,
assessing genotype quality, and depositing the geno-
types into the NIDA Repository; c) all costs for geno-
typing, taking into account delivery of the DNA,
genotyping SNPs, repeating failed samples, assessing
genotype quality, deposition of the data, costs of the
genotyping facility preferred. Depending on the GEDI
Steering Committee recommendations, the genotyp-
ing facility may not be the one initially proposed.
Budgets for future years may be contingent on the
genotyping strategy chosen. Applicants should be
aware that future years of allocation of funds for this
component may be changed to reflect the scientific
approach chosen and the funds needed; d) a detailed
analytic plan addressing issues related to the large
amount of GEDI data to be generated, such as multi-
ple-testing issues, assessing correlations and complex
interactions (gene × environment, gene × develop-
ment, environment × development, gene × environ-
ment × development), impact of population ancestry
(stratiﬁcation), false positives, etc.; e) a rationale for
single SNP, multiple SNP (e.g., from multiple path-
ways) and/or haplotype-based analyses; 16) All pheno-
typic, environmental, developmental, and genotypic
data analyzed through GEDI will be made available in
de-identified form to the scientific community
through the NIDA Repository. All investigators,
whether or not they join the NGC, will be required to
provide a timeline for submitting cleaned data to the
NIDA Repository, and to participate in the NGC
biannual meetings in Rockville, MD; travel and
accommodations should be included in the budget;
17) All applicants are encouraged to join the NIDA
Genetics Consortium (NGC) and to submit blood
samples as well as the required genetic, environmental,
and developmental data to the NIDA Repository.
Funds for up to 15,000 total samples (or 3,000–5,000
per award) for blood processing, DNA extraction, stor-
age, and distribution will be provided for all awards
joining the NGC. A budget needs to be presented if
> 5,000 samples will be collected. Additionally, a fee
structure for distribution of DNA from the NIDA
Repository can be found at http://www.nida.nih.gov/
about/organization/Genetics/FAQ_NCGS.html and
applicants should determine whether additional bud-
getary allocations are needed for DNA requests exceed-
ing the NIDA Repository allowances. Studies funded
under this FOA will not require NIDA Access
Committee review; 18) In cases where NGC member-
ship is prohibited (e.g., by laws governing foreign-
derived samples) or not chosen, applicants must
a) demonstrate that genetic, environmental, and devel-
opmental data can be submitted to the NIDA reposi-
tory; b) demonstrate that DNA samples have been or
will be submitted to a publicly available repository that
permits data sharing to qualiﬁed researchers; c) present
the repository’s quality control procedures for process-
ing DNA, cryopreserving or immortalizing blood, and
archiving DNA samples; and d) describe the reposi-
tory’s track record of providing data access by qualiﬁed
investigators.
Close interaction among GEDI Investigators will
be required to develop appropriate strategies and tools
to design and conduct GEDI research. The awardees
will convene as a GEDI Steering Committee, which
will include representatives from each of the awards
and the NIH, will meet twice a year and participate on
monthly conference calls to share information on data
resources, methodologies, analytical tools, as well as
data and preliminary results. Subcommittees and
working groups may be established, such as a genotyp-
ing or analysis group. A 4–5 member GEDI Advisory
Board will also be created by the GEDI Steering
Committee. Costs associated with attending meetings
and monthly conference calls should be included in
the proposed research budget. An additional budgetary
item should include costs to support two of the GEDI
Advisory Board members who will convene annually. 
The GEDI has the primary goal of elucidating
the contribution of genetic, environmental, and
developmental factors to the etiology of substance
abuse and related phenotypes. Funded research
under the GEDI is expected to lead to improved and
tailored preventive and treatment interventions for
these common and costly outcomes. 
GEDI applications must address the interplay of
genetic, environmental, and developmental factors
related to substance abuse and related phenotypes.
Although individual components (e.g., genetic, envi-
ronmental or developmental or their combination)
may be examined within the application, the ultimate
goal of the study must integrate these components.
Where possible, investigators are encouraged to
explore how relationships differ by sex/gender and
race/ethnic group.
Examples of appropriate research topics include,
but are not limited to, the following: 1) studies of the
role of gene–environment–development interactions in
the initiation of drug use and progression to addiction,
including but not restricted to studies of the impact of
environmental factors in individuals with known geno-
types for particular alleles; 2) studies of the role of
gene-environment correlation that clarify how
individuals select and influence their environments
over developmental stages, and to help identify true
gene–environment–development interactions;
3) studies employing reﬁned and systematic environ-
mental and developmental measures that identify
salient factors (e.g., trauma, peers, siblings) associated
with risk for substance abuse, stratiﬁed by genotypes
associated with substance abuse or related disorders;
4) studies to address the salience of initial drug expo-
sure (e.g., developmental timing, type, amount, con-
text, subjective and objective responses) for
subsequent substance abuse risk and course, incorpo-
rating the role of genetic risk (genotype; gene–envi-
ronment correlations and interactions); 5) studies that
explore the heterogeneity of genetic, environmental,
and developmental contributions to substance abuse
for different subgroups, including race/ethnic groups,
sex/gender groups, cultural groups, etc.; 6) identiﬁca-
tion of biomarkers, endophenotypes, and subclinical
phenotypes that vary or change over development as a
function of environmental and genetic risk; 7) studies
distinguishing the genetic, environmental, and devel-
opmental factors and their interactions in the vulnera-
bility to substance abuse on specific drugs versus
factors contributing to general liability; 8) studies that
examine the differential effects of salient developmen-
tal (e.g., pubertal timing) and environmental (e.g.,
stress, peer inﬂuences) events interacting with other
variables that confer or protect from vulnerability to
substance abuse and related phenotypes; 9) studies
that explicate the mechanisms by which genes, envi-
ronment, and development confer risk for substance
abuse and related phenotypes (e.g., delinquency, gam-
bling, HIV risk behaviors); 10) studies of the interplay
of genetic, environmental and developmental factors
on differential patterns of risk associated with comor-
bid psychiatric disorders, including psychotic and
internalizing disorders; 11) studies of the interplay of
genetic, environmental, and developmental factors on
differential patterns of risk associated with the timing
and dosages of prescribed medications, including but
not limited to psychostimulants; 12) studies of under-
lying vulnerability factors and endophenotypes that
may mediate genetic risk for substance abuse and
related phenotypes, including studies of temperament
and neurophysiology; 13) studies that explore the
impact of population differences in allele frequencies
on gene × environment × development interactions
for substance abuse and related phenotypes; 14)
research using molecular approaches to study the
impact of cumulative, acute, and/or chronic environ-
mental exposures or psychosocial stressors in speciﬁc
developmental periods; 15) research evaluating envi-
ronment and development data that include the
analysis of combined effects of gene variants from a
gene family or cellular pathways involved in addic-
tion; 16) studies of in utero drug exposure that iden-
tify genetic and environmental factors that
discriminate individuals who do and do not develop
substance abuse and related phenotypes; 17) studies
that explore whether effective interventions focusing
on social or other environmental elements work by
altering gene expression, or whether genetic variability
accounts for why interventions work for some partici-
pants and not for others; 18) studies that address the
interplay of genetic, environmental, and developmen-
tal factors within intervention outcome data sets, tak-
ing advantage of the unique opportunity within
intervention research to infer causal influence by
demonstrating changes in mediators that are related to
outcomes of interest; 19) studies of the interplay of
genetic, environmental, and developmental factors
associated with increased risk for behavioral disorders
in offspring exposed to smoking in utero; 20) studies of
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mental factors conferring resilience in individuals at
high risk for substance abuse and related outcomes;
21) evaluation of functional polymorphisms that are
moderated by environmental and developmental fac-
tors; 22) studies analyzing the genetic mechanisms by
which environmental factors such as therapeutic com-
pounds, stress, alcohol, and drugs alter the expression
of genes, e.g., through changing methylation status;
23) approaches that speciﬁcally model combinations of
a) single SNPs, multiple SNPs, and/or haplotypes and
environmental exposures; b) single SNPs, multiple
SNPs, and/or haplotypes and developmental trajecto-
ries; c) single SNPs, multiple SNPs, and/or haplotypes
and environment and development variables.
NIDA staff will conduct an application informa-
tion teleconference at a date and time to be determined.
This meeting will allow potential applicants to discuss
and clarify any issues related to this FOA with NIDA
staff. Detailed information about the meeting will be
updated and available on the NIDA website (http://
www.nida.nih.gov/about/organization/Genetics/
index.html), and a set of frequently asked questions and
staff responses will be posted. Please submit your ques-
tions via email to Dr. Weinberg (nw46w@nih.gov) at
least one day in advance of the teleconference.
This funding opportunity will use the U01
Research Project Cooperative Agreement award
mechanism. As an applicant, you will be solely
responsible for planning, directing, and executing
the proposed project. 
This funding opportunity uses the just-in-time
budget concepts. It also uses the nonmodular budget
format described in the PHS 398 application instruc-
tions (see http://grants.nih.gov/grants/funding/
phs398/phs398.html). A detailed categorical budget
for the "Initial Budget Period" and the "Entire
Proposed Period of Support" is to be submitted with
the application. 
The PHS 398 application instructions are avail-
able at http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. Applicants must
use the currently approved version of the PHS 398. 
For further assistance contact GrantsInfo, 301-
435-0714, (telecommunications for the hearing
impaired: TTY 301-451-0088), or by e-mail:
GrantsInfo@nih.gov.
Applications must be prepared using the most
current PHS 398 research grant application instruc-
tions and forms. Applications must have a D&B
Data Universal Numbering System (DUNS) num-
ber as the universal identifier when applying for
Federal grants or cooperative agreements. The D&B
number can be obtained by calling 866-705-5711 or
through the website at http://www.dnb.com/us/.
The D&B number should be entered on line 11 of
the face page of the PHS 398 form. 
The letter of intent receipt date for this RFA is
15 February 2007, with the application receipt date
15 March 2007. The complete version of the RFA is
available at http://grants/nih.gov/grants/guide/
rfa-ﬁles/RFA-DA-07-012.
Contacts: Naimah Weinberg, Division of
Epidemiology, Services, and Prevention Research,
National Institute on Drug Abuse, 6001 Executive
Boulevard, Room 5185, Bethesda, MD 20892-9589
USA, 301-402-1908, fax: 301-443-2636, e-mail:
nw46w@nih.gov; Glen D. Morgan, Tobacco Control
Research Branch, Behavioral Research Program,
Division of Cancer Control and Population Sciences,
National Cancer Institute, 6130 Executive Boulevard,
Room 4034, Bethesda, MD 20892-7337 USA, 301-
496-8585, fax: 301-496-86756, e-mail: gmorgan@
mail.nih.gov. Reference: RFA-DA-07-012.
International Research Scientist Development
Award (IRSDA) [K01] 
The International Research Scientist Development
Award (IRSDA) provides research opportunities, as
well as cutting-edge technical training, in leading devel-
oping country institutions for U.S. postdoctoral bio-
medical, epidemiological, clinical, social, and behavioral
scientists who are committed to careers in international
health research. The award supports the recipient for a
3- to 4-year period of collaboration with a U.S. mentor
and an established developing country mentor. This
collaboration should be based on a research project of
mutual interest in the context of an ongoing research
relationship between the U.S. and foreign mentors. It is
expected that this experience will prepare scientists to
pursue an independently funded global health research
career involving ongoing collaboration with developing
country scientists.
The IRSDA is part of the FIC strategy to sup-
port research collaborations in developing countries
in order to build research capacity to address global
health research priorities. The role of the IRSDA is
to: 1) attract new research talent to global health
research and enhance research collaboration between
the U.S. and foreign sites; 2) advance the career
paths of exceptional junior U.S. scientists with men-
tored training in health issues of developing country
populations; 3) extend the impact and scope of exist-
ing career research and training support for U.S. sci-
entists committed to international research; and
4) stimulate a more effective translation of the results
of research on global health problems into public
health practice.
With IRSDA support, the investigator will have
the opportunity to work closely with an established
foreign scientist in the developing world and a U.S.
investigator, who are involved in collaborative
research. The applicant will conduct research and
receive training at both the United States and devel-
oping country institutions. It is expected that these
awards will serve to forge collaborative relationships
between established, developing country researchers
and outstanding U.S. junior scientists who are
potential leaders of basic, clinical and behavioral/
social health research programs in the U.S.
Collaborations are expected to lead to advances that
will reduce the impact of global health problems and
narrow the gap in health disparities between devel-
oped and developing countries. 
All career development proposals must be tai-
lored to meet the individual needs of the candidate.
The specific career development and research train-
ing activities proposed in the application may be
new to the candidate or an extension of the candi-
date’s prior research, but should focus on global
health concerns which include, but are not limited
to, infectious diseases, nutrition, chronic/degenera-
tive conditions, trauma/injury and mental health
disorders. Basic laboratory, behavioral/social and
clinical biomedical research will be supported in
clinical, ﬁeld or laboratory settings. 
The candidate must devote a minimum of 75%
of full professional effort to the goals of this award,
including signiﬁcant time devoted to research in the
chosen developing country. Applicants for initial
awards must agree to spend a minimum of 50% of
the project period of the grant at the foreign research
site for at least 3 months per year. Applicants for a
competitive 3-year renewal mentored career develop-
ment award must agree to spend a minimum of 1
year of the total project period at the foreign research
site for at least 3 months per year. 
The candidate and the U.S. and foreign mentors
are jointly responsible for the preparation of the plan
for career development. The applicant must justify
the need for this award and provide a convincing
case that the proposed period of support will sub-
stantially enhance his or her career as an indepen-
dent investigator in global health research. The
sponsoring institution must be able to demonstrate a
commitment to the development of the candidate as
a productive, independent investigator. FIC recog-
nizes that there will be signiﬁcant differences in the
applicants, U.S. and foreign institutional environ-
ments, U.S. and foreign mentors’ backgrounds, and
approaches to international research collaboration
among applications. Therefore, applicants should
clearly define specific research and training goals
related to each mentor and each institution, methods
to achieve the goal of an independent research career
in global health, and specific measurable objectives
to enable assessment of the proposed project.
This funding opportunity will use the NIH
career development (K01) award mechanism (PA-
06-001). Please note that this K01 award has some
important differences from the K01 award described
in PA-06-001. These include: 1) the original award
period is for 3 to 4 years; 2) a competitive renewal
mentored career development award is possible for
up to 3 years; 3) Both a U.S. and a foreign mentor
are required and must share a research collaboration;
and 4) requirement of significant time spent in the
foreign country.
This funding opportunity uses the just-in-time
budget concepts. It also uses the nonmodular budget
format described in the PHS 398 application
instructions (see http://grants.nih.gov/grants/fund-
ing/phs398/phs398.html). A detailed categorical
budget for the "Initial Budget Period" and the
"Entire Proposed Period of Support" is to be sub-
mitted with the application.
Initial awards are for 3 to 4 years. Competitive
renewal awards are allowable for awardees who have
obtained a tenure-track position and additional men-
tored support can be for up to 3 years. Awards are not
transferable from one principal investigator to another.
The PHS 398 application instructions are avail-
able at http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. Applicants
must use the currently approved version of the PHS
398. For further assistance contact GrantsInfo, 301-
435-0714, (telecommunications for the hearing
impaired: TTY 301-451-0088, or by e-mail:
GrantsInfo@nih.gov.
Applications must be prepared using the most
current PHS 398 research grant application instruc-
tions and forms. Applications must have a D&B
Data Universal Numbering System (DUNS) num-
ber as the universal identifier when applying for
Federal grants or cooperative agreements. The D&B
number can be obtained by calling 866-705-5711 or
through the web site at http://www.dnb.com/us/.
The D&B number should be entered on line 11 of
the face page of the PHS 398 form.
The letter of intent dates for this PAR are 14
December 2007, and 16 December 2008, with the
application receipt dates 16 January 2007, 2008, and
2009. The complete version of this PAR is available
at http://grants.nih.gov/grants/guide/pa-files/PAR-
07-014.html. 
Contact: Barbara Sina, Division of International
Training and Research, Fogarty International
Center, National Institutes of Health, 31 Center
Drive, Room B2C39, Bethesda, MD 20892-2220,
301-496-1653, fax: 301-402-0779, e-mail:
sinab@mail.nih.gov. Reference: PAR-07-014.
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